Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2016

Open Access 01-12-2016 | Research article

Single-dose acarbose decreased glucose-dependent insulinotropic peptide and glucagon levels in Chinese patients with newly diagnosed type 2 diabetes mellitus after a mixed meal

Authors: Zhong Chen, Xiaoying Fu, Jian Kuang, Ju Chen, Hongmei Chen, Jianhao Pei, Huazhang Yang

Published in: BMC Endocrine Disorders | Issue 1/2016

Login to get access

Abstract

Background

Acarbose slows down the intestinal absorption of carbohydrates, but its effects on the secretion of incretins are still poorly known. This study aimed to examine the effects of single-dose acarbose on the secretion of incretins in patients with newly diagnosed type 2 diabetes mellitus (T2DM).

Methods

In this pilot study, twenty-three patients diagnosed with T2DM were randomly assigned to the oral glucose tolerance test (OGTT) group (n = 11) and the mixed meal test (MMT) group (n = 12). Fourteen subjects with normal OGTT were included as controls. Plasma glucose, insulin, glucagon, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic peptide (GIP) were measured at 0 (fasting), 15, 30, 60, 90, and 120 min after nutrient load. A week later, controls underwent MMT, the OGTT group underwent OGTT receiving 100 mg acarbose, and the MMT group underwent MMT receiving 100 mg acarbose. The same blood markers were measured again.

Results

No significant difference was observed in the OGTT group before and after administering acarbose. In the MMT group, postprandial levels of glucose (P < 0.01), insulin (P < 0.01), glucagon at 15 min (P < 0.05), glucagon area under the curve (AUC) (P < 0.05), GIP levels at 30 min (P < 0.05), and GIP AUC (P < 0.05) were decreased after receiving acarbose with a mixed meal, but GLP-1 levels and GLP-1 AUC did not change.

Conclusions

Single-dose acarbose could reduce the secretion of GIP and glucagon after a mixed meal in patients with newly diagnosed T2DM. The influence of acarbose on incretin levels could be related to the types of carbohydrate being consumed.

Trial registration

This study was registered with the Chinese Clinical Trial Registry (Registration Number: ChiCTR-TRC-14004260, Date of Registration: 2014-01-19).
Literature
1.
go back to reference De Leon DD, Crutchlow MF, Ham JY, Stoffers DA. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol. 2006;38:845–59.CrossRefPubMed De Leon DD, Crutchlow MF, Ham JY, Stoffers DA. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol. 2006;38:845–59.CrossRefPubMed
3.
go back to reference Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819–37.CrossRefPubMed Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819–37.CrossRefPubMed
4.
5.
go back to reference Ahren B. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. Diabetes Metab. 2013;39:195–201.CrossRefPubMed Ahren B. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. Diabetes Metab. 2013;39:195–201.CrossRefPubMed
6.
go back to reference Ranganath L, Norris F, Morgan L, Wright J, Marks V. Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect. Diabet Med. 1998;15:120–4.CrossRefPubMed Ranganath L, Norris F, Morgan L, Wright J, Marks V. Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect. Diabet Med. 1998;15:120–4.CrossRefPubMed
8.
go back to reference Thomsen C, Rasmussen O, Lousen T, Holst JJ, Fenselau S, Schrezenmeir J, et al. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr. 1999;69:1135–43.PubMed Thomsen C, Rasmussen O, Lousen T, Holst JJ, Fenselau S, Schrezenmeir J, et al. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr. 1999;69:1135–43.PubMed
9.
go back to reference Beysen C, Karpe F, Fielding BA, Clark A, Levy JC, Frayn KN. Interaction between specific fatty acids, GLP-1 and insulin secretion in humans. Diabetologia. 2002;45:1533–41.CrossRefPubMed Beysen C, Karpe F, Fielding BA, Clark A, Levy JC, Frayn KN. Interaction between specific fatty acids, GLP-1 and insulin secretion in humans. Diabetologia. 2002;45:1533–41.CrossRefPubMed
10.
go back to reference Zheng MY, Yang JH, Shan CY, Zhou HT, Xu YG, Wang Y, et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol. 2013;12:73.CrossRefPubMedPubMedCentral Zheng MY, Yang JH, Shan CY, Zhou HT, Xu YG, Wang Y, et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc Diabetol. 2013;12:73.CrossRefPubMedPubMedCentral
11.
go back to reference Wang D, He Y, Li Y, Luan D, Yang X, Zhai F, et al. Dietary patterns and hypertension among Chinese adults: a nationally representative cross-sectional study. BMC Public Health. 2011;11:925.CrossRefPubMedPubMedCentral Wang D, He Y, Li Y, Luan D, Yang X, Zhai F, et al. Dietary patterns and hypertension among Chinese adults: a nationally representative cross-sectional study. BMC Public Health. 2011;11:925.CrossRefPubMedPubMedCentral
12.
go back to reference Wang H, Deng F, Qu M, Yang P, Yang B. Association between dietary patterns and chronic diseases among Chinese adults in Baoji. Int J Chronic Dis. 2014;2014:548269.PubMedPubMedCentral Wang H, Deng F, Qu M, Yang P, Yang B. Association between dietary patterns and chronic diseases among Chinese adults in Baoji. Int J Chronic Dis. 2014;2014:548269.PubMedPubMedCentral
13.
go back to reference World Health Organisation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization; 1999. World Health Organisation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization; 1999.
14.
go back to reference DeLeon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 2002;56:101–6.CrossRefPubMed DeLeon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract. 2002;56:101–6.CrossRefPubMed
15.
go back to reference Patriti A, Facchiano E, Annetti C, Aisa MC, Galli F, Fanelli C, et al. Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg. 2005;15:1258–64.CrossRefPubMed Patriti A, Facchiano E, Annetti C, Aisa MC, Galli F, Fanelli C, et al. Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg. 2005;15:1258–64.CrossRefPubMed
16.
go back to reference Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab. 2006;290:E550–9.CrossRefPubMed Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab. 2006;290:E550–9.CrossRefPubMed
17.
go back to reference Bahr I, Muhlbauer E, Schucht H, Peschke E. Melatonin stimulates glucagon secretion in vitro and in vivo. J Pineal Res. 2011;50:336–44.CrossRefPubMed Bahr I, Muhlbauer E, Schucht H, Peschke E. Melatonin stimulates glucagon secretion in vitro and in vivo. J Pineal Res. 2011;50:336–44.CrossRefPubMed
18.
go back to reference Laube H. Acarbose: structure, mode of action and pharmacological properties. Clin Drug Investig. 2002;22:141–56.CrossRef Laube H. Acarbose: structure, mode of action and pharmacological properties. Clin Drug Investig. 2002;22:141–56.CrossRef
19.
go back to reference Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88:2706–13.CrossRefPubMed Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88:2706–13.CrossRefPubMed
20.
go back to reference Hucking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, et al. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7–36 amide) and to delay gastric emptying in Type 2 diabetic patients. Diabet Med. 2005;22:470–6.CrossRefPubMed Hucking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, et al. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7–36 amide) and to delay gastric emptying in Type 2 diabetic patients. Diabet Med. 2005;22:470–6.CrossRefPubMed
21.
go back to reference Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab. 2002;4:329–35.CrossRefPubMed Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab. 2002;4:329–35.CrossRefPubMed
22.
go back to reference Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagon-like peptide 1 (7–36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabet Med. 1998;15:485–91.CrossRefPubMed Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagon-like peptide 1 (7–36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabet Med. 1998;15:485–91.CrossRefPubMed
23.
go back to reference Cui Z, Dibley MJ. Trends in dietary energy, fat, carbohydrate and protein intake in Chinese children and adolescents from 1991 to 2009. Br J Nutr. 2012;108:1292–9.CrossRefPubMedPubMedCentral Cui Z, Dibley MJ. Trends in dietary energy, fat, carbohydrate and protein intake in Chinese children and adolescents from 1991 to 2009. Br J Nutr. 2012;108:1292–9.CrossRefPubMedPubMedCentral
24.
25.
go back to reference Hiki M, Shimada K, Kiyanagi T, Fukao K, Hirose K, Ohsaka H, et al. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). Circ J. 2010;74:1471–8.CrossRefPubMed Hiki M, Shimada K, Kiyanagi T, Fukao K, Hirose K, Ohsaka H, et al. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH). Circ J. 2010;74:1471–8.CrossRefPubMed
26.
go back to reference Narita T, Katsuura Y, Sato T, Hosoba M, Fujita H, Morii T, et al. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med. 2009;26:187–8.CrossRefPubMed Narita T, Katsuura Y, Sato T, Hosoba M, Fujita H, Morii T, et al. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med. 2009;26:187–8.CrossRefPubMed
27.
go back to reference Falko JM, Crockett SE, Cataland S, Mazzaferri EL. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. J Clin Endocrinol Metab. 1975;41:260–5.CrossRefPubMed Falko JM, Crockett SE, Cataland S, Mazzaferri EL. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. J Clin Endocrinol Metab. 1975;41:260–5.CrossRefPubMed
28.
go back to reference Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8:738–42.CrossRefPubMed Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8:738–42.CrossRefPubMed
29.
go back to reference Knop FK, Aaboe K, Vilsboll T, Volund A, Holst JJ, Krarup T, et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab. 2012;14:500–10.CrossRefPubMed Knop FK, Aaboe K, Vilsboll T, Volund A, Holst JJ, Krarup T, et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab. 2012;14:500–10.CrossRefPubMed
30.
go back to reference Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008;57:678–87.CrossRefPubMed Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008;57:678–87.CrossRefPubMed
31.
go back to reference Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, Volund A, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56:1951–9.CrossRefPubMed Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, Volund A, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56:1951–9.CrossRefPubMed
32.
go back to reference Yabe D, Seino Y, Fukushima M, Seino S. beta cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15:602.CrossRefPubMed Yabe D, Seino Y, Fukushima M, Seino S. beta cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15:602.CrossRefPubMed
33.
go back to reference Ueno H, Tsuchimochi W, Wang HW, Yamashita E, Tsubouchi C, Nagamine K, et al. Effects of miglitol, acarbose, and sitagliptin on plasma insulin and gut peptides in type 2 diabetes mellitus: a crossover study. Diabetes Ther. 2015;6:187–96.CrossRefPubMedPubMedCentral Ueno H, Tsuchimochi W, Wang HW, Yamashita E, Tsubouchi C, Nagamine K, et al. Effects of miglitol, acarbose, and sitagliptin on plasma insulin and gut peptides in type 2 diabetes mellitus: a crossover study. Diabetes Ther. 2015;6:187–96.CrossRefPubMedPubMedCentral
Metadata
Title
Single-dose acarbose decreased glucose-dependent insulinotropic peptide and glucagon levels in Chinese patients with newly diagnosed type 2 diabetes mellitus after a mixed meal
Authors
Zhong Chen
Xiaoying Fu
Jian Kuang
Ju Chen
Hongmei Chen
Jianhao Pei
Huazhang Yang
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2016
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-016-0133-7

Other articles of this Issue 1/2016

BMC Endocrine Disorders 1/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.